- Previous Close
148.60 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 201.40 - Volume
6,187 - Avg. Volume
1,803 - Market Cap (intraday)
15.076B - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
47.89 - EPS (TTM)
3.22 - Earnings Date Feb 19, 2025
- Forward Dividend & Yield 1.60 (1.84%)
- Ex-Dividend Date Apr 28, 2023
- 1y Target Est
--
Biotage AB (publ) provides solution and product in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems; sample preparation product; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, academic, environmental protection, food safety, and agriculture, as well as clinical, forensic, and academic laboratories. It operates in 80 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
www.biotage.comRecent News: 0GRP.IL
View MorePerformance Overview: 0GRP.IL
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0GRP.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0GRP.IL
View MoreValuation Measures
Market Cap
12.41B
Enterprise Value
12.29B
Trailing P/E
45.91
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.71
Price/Book (mrq)
3.17
Enterprise Value/Revenue
5.80
Enterprise Value/EBITDA
23.05
Financial Highlights
Profitability and Income Statement
Profit Margin
13.90%
Return on Assets (ttm)
4.66%
Return on Equity (ttm)
8.27%
Revenue (ttm)
1.55B
Net Income Avi to Common (ttm)
216M
Diluted EPS (ttm)
3.22
Balance Sheet and Cash Flow
Total Cash (mrq)
444M
Total Debt/Equity (mrq)
9.99%
Levered Free Cash Flow (ttm)
276.88M